Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 44Cholangiocarcinoma 5Liver Neoplasms 4Advanced Biliary Tract Cancer 3Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Liver Cirrhosis 1Klatskin Tumor 1Hepatoblastoma 1HER2-negative Advanced Gastric Cancer 1Gastric Cancer Metastatic to Liver 1Gallbladder Neoplasms 1First-line Treatment 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Tumor 1Biliary Tract Neoplasms Immunotherapy 1Advanced Primary Liver Cancer 1

Interventions

elemene 2lenvatinib 1Oxaliplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Primary Liver Cancer × lenvatinib × Clear all
NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Shandong Public Health Clinical Center

Phase EARLY_PHASE1 Unknown
12 enrolled

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡